- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Hormone Receptor-Positive Breast in Netherlands
Total 57 results
-
Leiden University Medical CenterThe Netherlands Cancer Institute; Borstkanker Onderzoek Groep; Comprehensive... and other collaboratorsSuspendedHER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer | Neoadjuvant Chemotherapy | Fasting Mimicking Diet | Pathological Complete Response | Objective Response RateNetherlands
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive Breast CancerUnited States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
-
Amsterdam UMC, location VUmcNovartis; Borstkanker Onderzoek GroepUnknownMetastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastNetherlands
-
Eli Lilly and CompanyCompletedBreast Cancer | Early-Stage Breast Carcinoma | Hormone Receptor Positive TumorUnited States, Canada, Korea, Republic of, Italy, Austria, Belgium, Germany, Netherlands, Spain, Taiwan
-
Novartis PharmaceuticalsCompletedEstrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA GeneUnited States, Netherlands, Spain, Germany, United Kingdom
-
The Netherlands Cancer InstituteAstraZeneca; Daiichi SankyoRecruiting
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
The Netherlands Cancer InstituteCompletedBreast Cancer | HER2 PositiveNetherlands
-
Jules Bordet InstituteRoche Pharma AGActive, not recruitingHER-2 Positive Breast CancerBelgium, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER-2 Positive Breast CancerBelgium, Netherlands, Australia, Italy, United States
-
The Netherlands Cancer InstituteRoche Pharma AG; Borstkanker Onderzoek GroepActive, not recruitingBreast Cancer | HER2 PositiveNetherlands
-
ExelixisActive, not recruitingA Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm MalignantUnited States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
The Netherlands Cancer InstituteCompletedBreast Cancer | Ovarian Cancer | Advanced CancerNetherlands
-
The Netherlands Cancer InstituteRoche Pharma AGCompletedBreast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial CancerNetherlands
-
ExelixisRecruitingCervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid TumorsUnited States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast Cancer or Gastric CancerTaiwan, Netherlands, Italy, United States, Belgium, United Kingdom, Korea, Republic of, France, Spain
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Leiden University Medical CenterCompletedBreast Cancer | Ovarian Cancer | Neoplasm MalignantNetherlands
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
University Medical Center GroningenNot yet recruitingRenal Cell Carcinoma | Breast Carcinoma | Thyroid Carcinoma | Ovarian Carcinoma | Endometrium CarcinomaNetherlands
-
European Organisation for Research and Treatment...CompletedBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | ThromboembolismNetherlands
-
AstraZenecaCompletedAdvanced Ovarian Cancer | Paclitaxel | Carboplatin | Triple Negative Metastatic Breast CancerBelgium, Netherlands, United Kingdom
-
AmgenRecruitingSolid TumorsCanada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Italy, Finland and more
-
University Medical Center GroningenCompletedBreast Cancer | Testicular CancerNetherlands
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Radboud University Medical CenterUnknownOvarian Cancer | Endometrial Cancer | Advanced/Recurrent Breast CancerNetherlands
-
University Medical Center GroningenUMCG Kanker ResearchfondsRecruitingCervical Cancer | Leukemia | Cancer | Breast Cancer | Hodgkin Lymphoma | Osteosarcoma | Ewing Sarcoma | Testicular CancerNetherlands
-
AmgenTerminatedMUC17-positive Solid TumorsUnited States, Korea, Republic of, Taiwan, Spain, Austria, France, Japan, Germany, Netherlands
-
Novartis PharmaceuticalsCompletedMelanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
-
AstraZenecaRecruitingBreast Cancer | Bladder CancerUnited States, Netherlands, United Kingdom
-
Bristol-Myers SquibbCompletedChronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positiveNetherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
-
GenmabRecruitingSquamous Non Small Cell Lung Cancer (NSCLC-SCC) | Breast Cancer, Breast Neoplasms | Endometrial Cancer, Endometrial Neoplasm | Ovarian Cancer, Ovarian NeoplasmsUnited States, France, Spain, Netherlands, Belgium, United Kingdom, Denmark, Italy, Poland
-
Novartis PharmaceuticalsCompletedBreast Cancer | Ovarian Cancer | Colon Cancer | Endometrium CancerCanada, Netherlands, Spain, United States
-
Tesaro, Inc.European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaboratorsTerminatedOvarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of BreastUnited States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
-
AbbVieCompletedBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Solid TumorsUnited States, Netherlands, Spain
-
AbbVieCompletedBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Colon Cancer | Solid TumorsUnited States, Netherlands, Spain
-
Novartis PharmaceuticalsActive, not recruitingMelanoma | Pancreatic Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Cancer | Esophageal Squamous Cell Cancer | BRAF Mutant Colorectal Cancer | Cervical Squamous Cell Cancer | Lung Squamous Cell CancerCanada, Italy, Spain, Germany, Netherlands, United States, France
-
Novartis PharmaceuticalsCompletedNeoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
-
CytomX TherapeuticsTerminatedBreast Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Solid Tumor, AdultUnited States, Spain, Netherlands, United Kingdom
-
Novartis PharmaceuticalsCompletedAcute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated MelanomaItaly, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
-
SanofiActive, not recruitingBreast Cancer Metastatic | Pancreatic Carcinoma MetastaticSpain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
-
Bristol-Myers SquibbCompletedChronic Myeloid Leukemia | Blast CrisisNetherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerCanada, Korea, Republic of, Taiwan, United States, Italy, United Kingdom, Thailand, Russian Federation, India, Belgium, Australia, Poland, Spain, Japan, Brazil, Czechia, Netherlands
-
Incyte Biosciences International SàrlRecruitingLymphoma | Acute Myeloid Leukemia | Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Solid Tumors | Chronic Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid LeukemiaSpain, Italy, France, Germany, United Kingdom, Belgium, Sweden, Denmark, Netherlands
-
AstraZenecaIqvia Pty LtdActive, not recruitingSCLC | Breast | Ovarian | Gastric CancersUnited Kingdom, United States, Korea, Republic of, France, Netherlands, Israel, Switzerland
-
Seagen Inc.RecruitingMelanoma | Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Ovarian Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Neoplasms | Esophageal Squamous Cell CarcinomaUnited States, Spain, Italy, Canada, United Kingdom, France, Belgium, Germany, Netherlands